Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Market Cap & Net Worth: Agios Pharmaceuticals, Inc. (0HB0)
Agios Pharmaceuticals, Inc. (LSE:0HB0) has a market capitalization of $1.69 Billion ($1.69 Billion) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #5850 globally and #153 in its home market, demonstrating a 3.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Agios Pharmaceuticals, Inc.'s stock price $29.01 by its total outstanding shares 58178700 (58.18 Million).
Agios Pharmaceuticals, Inc. Market Cap History: 2026 to 2026
Agios Pharmaceuticals, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $1.69 Billion to $1.69 Billion (0.00% CAGR).
Agios Pharmaceuticals, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Agios Pharmaceuticals, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0HB0 by Market Capitalization
Companies near Agios Pharmaceuticals, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Agios Pharmaceuticals, Inc. by market ranking:
- Intea Fastigheter B (ST:INTEA-B): Ranked #5841 globally with a market cap of $1.50 Billion USD ( Skr16.78 Billion SEK).
- Insignia Financial Ltd (AU:IFL): Ranked #5842 globally with a market cap of $1.50 Billion USD ( AU$2.42 Billion AUD).
- Novavax Inc (NASDAQ:NVAX): Ranked #5851 globally with a market cap of $1.49 Billion USD.
- Sejahteraraya Anugrahjaya Tbk (JK:SRAJ): Ranked #5852 globally with a market cap of $1.49 Billion USD ( Rp24.29 Trillion IDR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5841 | Intea Fastigheter B | ST:INTEA-B | $1.50 Billion | Skr73.25 |
| #5842 | Insignia Financial Ltd | AU:IFL | $1.50 Billion | AU$4.67 |
| #5851 | Novavax Inc | NASDAQ:NVAX | $1.49 Billion | $10.64 |
| #5852 | Sejahteraraya Anugrahjaya Tbk | JK:SRAJ | $1.49 Billion | Rp15075.00 |
Agios Pharmaceuticals, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Agios Pharmaceuticals, Inc.'s market cap moved from $1.69 Billion to $ 1.69 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Agios Pharmaceuticals, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.69 Billion USD |
| MoneyControl | $1.69 Billion USD |
| MarketWatch | $1.69 Billion USD |
| marketcap.company | $1.69 Billion USD |
| Reuters | $1.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.